The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...

Discontinuing tyrosine kinase inhibitor maintenance after extended complete molecular response should only be attempted as part of a clinical trial, the researchers say.

A new nonprofit organization is looking to help people adopt and support cats affected by feline immunodeficiency and feline ...

B-cell Acute Lymphoblastic Leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it ...

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it ...

Treatment of B-cell Acute Lymphoblastic Leukaemia has improved thanks to CAR-T therapies, but relapse is still very common.

A young girl from Amsterdam has died after a long hard-fought battle with leukemia.10-year-old Portia Robles died Saturday ...

In addition to exporting materials out of the nucleus, the protein, called Exportin-1 (also called Xpo1 or Crm1), seems to play a role in promoting gene transcription, the process that creates RNA ...

Zavier Sexton, Graham Smith, Bryce Miller and Natalie Vulhop were honored as young heroes at the 2025 CBJ Foundation ...

The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or ...

Twelve-year-old Lucas Polsinelli is in 7th grade and has been receiving treatment for B-cell Acute Lymphoblastic Leukemia at the Melodie’s Center at Albany Medical Center. He has just under 2 ...

Researchers who study Down syndrome at the University of Colorado Boulder advocate for more inclusion on World Down Syndrome ...